百明信康与药明生物签署战略合作 打造领先过敏诊疗平台
百明信康与药明生物签署战略合作
打造领先过敏诊疗平台
2021年3月19日，中国，杭州
创新制药公司百明信康 (Worg Pharma)和全球领先的开放式生物制药技术平台公司药明生物（WuXi Biologics, 2269.HK）共同宣布双方建立长期战略合作。
药明生物首席执行官陈智胜博士表示：“我们很高兴通过药明生物最新推出的微生物和病毒产业化平台赋能百明信康，加快这一新锐公司为全球过敏患者提供创新疗法。”
百明信康董事长兼首席执行官徐爱武博士表示：“非常高兴能与药明生物这样优秀且在生物药开发和生产领域具有丰富经验的生物技术平台型公司合作，这将更好地发挥各自的优势，加速我们创建世界领先的过敏诊疗平台。”
双方将基于药明生物建立的微生物和病毒产业化平台（Microbial and Viral Platforms, MVP），进行多个产品的工艺开发、生产和全球申报，打造新一代变应原特异性免疫疗法。
www.worgpharma.com
百明信康是一家创立于2018年的创新制药公司，总部位于杭州。公司创业合伙人团队，分别来自中国、美国和欧洲，在药物开发、临床试验、药政事务和市场准入等方面拥有深厚知识和丰富经验，同时也非常熟悉产品商业化，产业运营国际化全流程。公司致力于创新药的开发和商业化，基于自有的技术平台PCFiT，重点关注变应原的诊断与变应原特异性免疫治疗，打造全程管理的闭环式过敏诊疗平台。目前，公司已打造出包含多款在研产品的丰富产品线，其中梯牧草花粉脱敏药物已在欧洲完成临床II期研究。
www.wuxibiologics.com
药明生物（股票代码：2269.HK）作为一家香港上市公司，是全球领先的开放式、一体化生物制药能力和技术赋能平台。公司为全球生物制药公司和生物技术公司提供全方位的端到端研发服务，帮助任何人、任何公司发现、开发及生产生物药，实现从概念到商业化生产的全过程，加速全球生物药研发进程，降低研发成本，造福病患。
Worg Pharma Signs Strategic Partnership with WuXi Biologics
Build leading platform for allergy diagnostic and treatment
March 19, 2021, Hangzhou, CHINA
Innovative pharmaceutical company Worg Pharma (“Worg”) and Global company with leading open-access biologics technology platforms WuXi Biologics (“WuXi Bio”, stock code: 2269.HK) jointly announce that they have entered into a long-term strategic collaboration.
Dr. Chris Chen, CEO of WuXi Biologics said: “We are glad to enable Worg with our premier Microbial and Viral Platforms (MVP) to accelerate innovative treatments for allergy patients.”
Dr. Aiwu Xu, Chairman and CEO of Worg said: “Very happy to collaborate with WuXi Biologics, with the help of its leadership in biologics development and manufacturing, we both can bring the advantages into play to expedite developing robust platforms of allergy treatments.”
Leveraging WuXi Biologics’s well-established Microbial and Viral Platforms (MVP), both parties will conduct the process development, manufacturing and global IND for multiple biologics, further enabling Worg to advance the new-generation Allergy Immunotherapy (AIT).
www.worgpharma.com
Headquartered in Hangzhou China, Worg was founded in 2018 and led by an executive team from China, the United States and Europe who have extensive experience in life science executive, pharmaceutical development, clinical trials, regulatory affairs and commercialization. As an innovative pharmaceutical company, Worg is devoted to the development and commercialization of innovative drugs, focuses on allergens diagnosis and allergy immunotherapy in the base of self-owned PCFiT platform, builds a closed-loop allergy diagnosis and treatment platform with full management. Up to now, Worg has developed a comprehensive pipeline of PCFiT-based allergy vaccines for a number of inhalant allergens, one of the most advanced products, the grass pollen allergy has completed the Phase II clinical trial.
www.wuxibiologics.com
WuXi Biologics (stock code: 2269.HK), a Hong Kong-listed company, is a leading global open-access biologics technology platform offering end-to-end solutions to empower organizations to discover, develop, and manufacture biologics from concept to commercial manufacturing. The company’s history and achievements demonstrate its commitment to providing a truly one-stop service offering and strong value proposition to its global clients.